Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Radioactivity03:23

Types of Radioactivity

16.8K
The most common types of radioactivity are α decay, β decay, γ decay, neutron emission, and electron capture.
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:
16.8K
Biological Effects of Radiation02:59

Biological Effects of Radiation

15.4K
All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
15.4K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

112
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
112
Isotopes and Radioisotopes01:28

Isotopes and Radioisotopes

8.6K
In the early 1900s, English chemist Frederick Soddy realized that an element could have atoms with different masses that were chemically indistinguishable. These different types are called isotopes — atoms of the same element that differ in mass. Isotopes differ in mass because they have different numbers of neutrons but are chemically identical because they have the same number of protons. Soddy was awarded the Nobel Prize in Chemistry in 1921 for this discovery.
An isotope containing...
8.6K
Positron Emission Tomography01:29

Positron Emission Tomography

4.2K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.2K
Nuclear Transmutation03:20

Nuclear Transmutation

17.5K
Nuclear transmutation is the conversion of one nuclide into another. It can occur by the radioactive decay of a nucleus, or the reaction of a nucleus with another particle. The first manmade nucleus was produced in Ernest Rutherford’s laboratory in 1919 by a transmutation reaction, the bombardment of one type of nuclei with other nuclei or with neutrons. Rutherford bombarded nitrogen-14 atoms with high-speed α particles from a natural radioactive isotope of radium and observed...
17.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [<sup>225</sup>Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Erratum to Xiao Y, Benedict S, Cui Y, Glide-Hurst C, Graves S, Jia X, KryF S, Li H, Lin L, Matuszak M, Newpower M, Paganetti H, Qi XS, Roncali E, Rong Y, Sgouros G, Simone 2nd CB, Sunderland JJ, Taylor PA, Tchelebi L, Weldon M, Zou JW, Wuthrick EJ, Machtay M, Le QT, Buchsbaum JC. Embracing the future of clinical trials in radiation therapy: an NRG oncology CIRO technology retreat whitepaper on pioneering technologies and AI-driven solutions. Int J of Radiat Oncol Biol Phys 2025:122;443-457.

International journal of radiation oncology, biology, physics·2026
Same author

Combination Radiopharmaceutical Therapy and Radiotherapy for Thyroid Cancer: Dosimetry-Driven Precision Medicine.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Enhanced activity localization and microscale dosimetry in alpha-emitter radiopharmaceutical therapy using integrated autoradiography and histological imaging.

Scientific reports·2025
Same author

Respiratory Signal Estimation for Free-Hand 2D Ultrasound Image via Heterogeneous Alignment and Conditional Generative Learning.

IEEE transactions on bio-medical engineering·2025
Same author

Three-dimensional cell culture models in respiratory virus research: technological advances and current applications.

Journal of materials chemistry. B·2025
Same journal

<sup>18</sup>F-fluorodeoxyglucose PET in Major Psychiatric Disorders.

PET clinics·2026
Same journal

Five Decades of [18F]Fluorodeoxyglucose-PET in Neuropsychiatric Disorders: From Brain Metabolism to Precision Functional Imaging.

PET clinics·2026
Same journal

Brain [18F]FDG PET in Subjective Cognitive Complaints: From Diagnostic Gap to Neurobiological Insight.

PET clinics·2026
Same journal

FDG PET in Movement Disorders and Parkinsonian Syndromes.

PET clinics·2026
Same journal

Brain [18F]FDG PET in Encephalitis and Postinfectious Neurocognitive Syndromes.

PET clinics·2026
Same journal

Theranostics in Nuclear Medicine: Historical, Regulatory, and Evidence Context for the Practicing Nuclear Medicine Physician.

PET clinics·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K

Alpha and Beta Radiation for Theragnostics.

Hong Song1, George Sgouros2

  • 1Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA 94305, USA.

PET Clinics
|April 30, 2024
PubMed
Summary
This summary is machine-generated.

Targeted radionuclide therapy (TRT) has advanced with new isotopes and targeted alpha therapy (TAT), expanding cancer treatment options. Further research is needed to optimize TRT for diverse solid tumors and integrate it with other therapies like immunotherapy.

Keywords:
Actinium-225Alpha particleBeta particleLead-212Lutetium-177Targeted alpha therapyTargeted radionuclide therapyTerbium-161

More Related Videos

Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation
11:24

Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation

Published on: July 3, 2015

11.1K
Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition
11:45

Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition

Published on: November 14, 2013

12.2K

Related Experiment Videos

Last Updated: Jun 27, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K
Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation
11:24

Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation

Published on: July 3, 2015

11.1K
Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition
11:45

Functional Interrogation of Adult Hypothalamic Neurogenesis with Focal Radiological Inhibition

Published on: November 14, 2013

12.2K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Chemistry

Background:

  • Targeted radionuclide therapy (TRT) has evolved from iodine-131 to include advanced beta-emitting isotopes like lutetium-177, demonstrating success in treating neuroendocrine tumors (Lu-177-DOTATATE) and prostate cancer (Lu-177-PSMA-617).
  • The field has expanded to targeted alpha therapy (TAT), utilizing agents such as radium-223 for prostate cancer bone metastases and exploring other alpha emitters like Actinium-225 and Lead-212.
  • Emerging beta emitters like Copper-67 and Terbium-161 are also under investigation for TRT applications.

Purpose of the Study:

  • To review the evolution and current advancements in targeted radionuclide therapy (TRT) and targeted alpha therapy (TAT).
  • To highlight the expanding range of radioisotopes and carrier molecules used in TRT and TAT.
  • To identify the ongoing challenges and future directions in TRT, including its integration with other treatment modalities.

Main Methods:

  • Literature review of advancements in targeted radionuclide therapy (TRT) and targeted alpha therapy (TAT).
  • Analysis of the clinical success of key radiopharmaceuticals, including Lu-177-DOTATATE and Lu-177-PSMA-617.
  • Examination of emerging radioisotopes (Cu-67, Tb-161, Ac-225, Pb-212) and their therapeutic potential.

Main Results:

  • TRT has evolved significantly, with lutetium-177-based therapies showing notable success in specific cancers.
  • Targeted alpha therapy (TAT) is emerging as a promising modality, with agents like radium-223 already in clinical use.
  • Several new beta and alpha emitting radioisotopes are being explored to broaden the scope of TRT and TAT.

Conclusions:

  • TRT and TAT represent significant progress in cancer treatment, offering targeted approaches with improved efficacy.
  • Despite successes, the application of TRT in diverse solid tumors and its combination with other therapies like immunotherapy require further investigation.
  • Optimizing TRT delivery and overcoming existing challenges are crucial for maximizing its clinical impact and complementing treatments like antibody-drug conjugates.